Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Cash & Equivalents (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Cash & Equivalents for 3 consecutive years, with $153.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents fell 22.01% to $153.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $153.1 million, a 22.01% decrease, with the full-year FY2024 number at $152.6 million, down 45.09% from a year prior.
  • Cash & Equivalents was $153.1 million for Q3 2025 at Inhibrx Biosciences, down from $186.6 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $277.9 million in Q4 2023 to a low of $152.6 million in Q4 2024.
  • A 3-year average of $201.4 million and a median of $196.3 million in 2024 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: crashed 45.09% in 2024, then fell 17.76% in 2025.
  • Inhibrx Biosciences' Cash & Equivalents stood at $277.9 million in 2023, then tumbled by 45.09% to $152.6 million in 2024, then increased by 0.32% to $153.1 million in 2025.
  • Per Business Quant, the three most recent readings for INBX's Cash & Equivalents are $153.1 million (Q3 2025), $186.6 million (Q2 2025), and $216.5 million (Q1 2025).